The Government Shutdown Won't Stop This FDA Meeting

We may be in the midst of one of the biggest biotech bull markets in history, but shares of controversial biotech company Amarin (AMRN -0.87%) have plunged more than 40% in the past 12 months. A number of issues have pressured shares, ranging from question marks over the market exclusivity of the company's fish-oil drug Vascepa to emerging generic competition. Despite this drop, Amarin has the opportunity to prove the naysayers wrong this month during an FDA advisory committee meeting that may recommend expanded approval for Vascepa.

The company announced last week that the government shutdown wouldn't change the date of this meeting, so investors should be prepared for this major catalyst. In the following video, analysts David Williamson and Max Macaluso discuss the significance of this meeting to Amarin's business and also examine competition from GlaxoSmithKline's (GSK 0.35%) Lovaza and AstraZeneca's (AZN 0.73%) experimental fish-oil pill, Epanova.